Express News | Alto Neuroscience Highlights Data From Precision Psychiatry Platform At ACNP Annual Meeting; Interim Analysis For ALTO-300 Phase 2b Trial In MDD Expected Q1 2025, With Topline Results In H1 2025

BenzingaDec 11 08:14 ET

Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology

BusinesswireDec 11 08:03 ET

Potential Catalysts and Strategic Focus: Analyzing Alto Neuroscience's Upcoming Trials and Precision Psychiatry Approach

TipRanksNov 14 02:36 ET

Alto Neuroscience Strengthens Financial Position Amid Increased R&D

TipRanksNov 13 23:44 ET

Alto Neuroscience Analyst Ratings

BenzingaNov 13 10:18 ET · Ratings

Stifel Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Cuts Target Price to $10

Moomoo NewsNov 13 08:31 ET · Ratings